Phase 3 study of subcutaneous bortezomib, thalidomide, and prednisolone consolidation after subcutaneous bortezomib-based induction and autologous stem cell transplantation in patients with previously untreated multiple myeloma: the VCAT study
Version 2 2024-06-13, 15:00Version 2 2024-06-13, 15:00
Version 1 2021-11-29, 10:10Version 1 2021-11-29, 10:10
journal contribution
posted on 2024-06-13, 15:00authored byN Horvath, A Spencer, M Kenealy, D Joshua, PJ Campbell, JJ Lee, J Hou, L Qiu, A Kalff, T Khong, A Londhe, S Siggins, M van Kooten Losio, M Eisbacher, HM Prince
Phase 3 study of subcutaneous bortezomib, thalidomide, and prednisolone consolidation after subcutaneous bortezomib-based induction and autologous stem cell transplantation in patients with previously untreated multiple myeloma: the VCAT study